Search our Database of Scientific Publications and Authors

I’m looking for a

    29471 results match your criteria Graft Versus Host Disease

    1 OF 590

    Delay of Alternative Antiviral Therapy and Poor Outcomes of Acyclovir-Resistant Herpes Simplex Virus Infections in Recipients of Allogeneic Stem Cell Transplant.
    Transpl Int 2018 Feb 21. Epub 2018 Feb 21.
    Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas.
    Acyclovir is commonly used to prevent and treat herpes simplex virus (HSV) reactivation after hematopoietic cell transplant (HCT), and only few reports have been published on acyclovir-resistant HSV in HCT recipients. We reviewed the medical records of patients with a microbiologic diagnosis of acyclovir-resistant HSV by plaque reduction test who received an HCT from 2002 through 2014. A total of 4028 HCTs were performed during the study period, and 18 of the recipients met the diagnostic criteria for acyclovir-resistant HSV. Read More

    First-in-human Phase 1 Clinical Study of the IL-15 Superagonist Complex ALT-803 to Treat Relapse after Transplantation.
    Blood 2018 Feb 20. Epub 2018 Feb 20.
    Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN, United States;
    New therapies for patients with hematologic malignancies who relapse after allogeneic hematopoietic cell transplantation (allo-HCT) are needed. Interleukin (IL)-15 is a cytokine that stimulates CD8T cell and NK cell anti-tumor responses, and we hypothesized this cytokine may augment anti-leukemia/lymphoma immunity in vivo. To test this, we performed a first-in-human multi-center phase 1 trial (ClinicalTrials. Read More

    Neutrophils provide cellular communication between ileum and mesenteric lymph nodes at graft-versus-host disease onset.
    Blood 2018 Feb 20. Epub 2018 Feb 20.
    Department of Hematology, Oncology and Stem Cell Transplantation, Freiburg University Medical Center, Albert Ludwigs University (ALU) Freiburg, Germany
    Conditioning-induced damage of the intestinal tract plays a critical role during the onset of acute graft-versus-host disease (GVHD). Therapeutic interference with these early events of GVHD is difficult, and currently used immunosuppressive drugs mainly target donor T-cells. However not donor T-cells but neutrophils reach the sites of tissue injury first and therefore could be a potential target for GVHD-prevention. Read More

    Are graft-versus-host-disease patients missing out on the vital occupational therapy services? a systematic review.
    Int J Rehabil Res 2018 Feb 14. Epub 2018 Feb 14.
    Oncology Center, KFSHRC, Riyadh, Saudi Arabia.
    The aim of this review is to show the importance of occupational therapy/hand therapy for chronic graft-versus-host-disease (GVHD) patients and to outline the current state of the literature. GVHD of the hand can cause functional loss, reduced activities of daily life, poor social interaction, and loss of income because of limitations in work. Hand therapy, which is a specialty practised by both occupational therapists and physical therapists, has been proven to be an effective approach for hand-related musculoskeletal disorders; however, the literature search suggests that it is an underutilized specialty around the world. Read More

    Comparison between 8-methoxypsoralen and 5-aminolevulinic acid in killing T cells of photopheresis patients ex vivo.
    Lasers Surg Med 2018 Feb 20. Epub 2018 Feb 20.
    Department of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, N-0379, Norway.
    Background And Objective: Extracorporeal photopheresis (ECP), an established modality for cutaneous T-cell lymphoma (CTCL) and graft-versus-host disease, involves ex vivo treatment of isolated leukocytes of a patient with the photosensitizing drug 8-methoxypsoralen (8-MOP) and ultraviolet-A (UV-A) exposure before reinfusion back to the patient. However, 8-MOP binds to both diseased and normal cells and thus kills both types of the cells after UV-A illumination with little selectivity. Clinically, this modality gives only partial response in the majority of treated patients. Read More

    miR-142-3p regulates autophagy by targeting ATG16L1 in thymic-derived regulatory T cell (tTreg).
    Cell Death Dis 2018 Feb 19;9(3):290. Epub 2018 Feb 19.
    Liver Transplantation Center, First Affiliated Hospital, Nanjing Medical University, No. 300 Guangzhou Road, Jiangsu Province, Nanjing, 210029, China.
    Thymic-derived regulatory T cell (tTreg) clinical trials show therapeutic promise in the prevention of acute graft-versus-host disease (GVHD) in allogeneic hematopoietic stem cell transplantation patients. However, strategies are needed to improve tTreg proliferative ability and survival as a means to improve tTreg therapy and reduce the requirement for producing large numbers of Treg cells for adoptive tTreg transfer. Autophagy is a self-degradative process for cytosolic components, which is involved in cells death, differentiation, lymphocyte homeostasis, and tTreg function. Read More

    Immunoregulatory functions and the therapeutic implications of GARP-TGF-β in inflammation and cancer.
    J Hematol Oncol 2018 Feb 20;11(1):24. Epub 2018 Feb 20.
    Department of Microbiology and Immunology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, 29425, USA.
    GARP (glycoprotein-A repetitions predominant) is a type I transmembrane cell surface docking receptor for latent transforming growth factor-β (TGF-β) that is abundantly expressed on regulatory T lymphocytes and platelets. GARP regulates the availability of membrane-bound latent TGF-β and modulates its activation. For this reason, GARP expression on immune and non-immune cells is involved in maintaining peripheral tolerance. Read More

    Donor Genotype in the Interleukin-7 Receptor α-Chain Predicts Risk of Graft-versus-Host Disease and Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation.
    Front Immunol 2018 2;9:109. Epub 2018 Feb 2.
    Institute for Inflammation Research, Department of Rheumatology and Spine Disease, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
    The efficacy of allogeneic hematopoietic stem cell transplantation (HSCT) is challenged by acute and chronic graft-versus-host disease (aGVHD and cGVHD) and viral infections due to long-lasting immunodeficiency. Interleukin-7 (IL-7) is a cytokine essential forT cell generation in thymus and peripheral T cell homeostasis. In this study, we investigated the impact of the single nucleotide polymorphismin the IL-7 receptor α-chain (IL-7Rα) which has previously been associated with several autoimmune diseases. Read More

    Effects of Prophylactic Foscarnet on HHV-6 Reactivation and HHV-6 Encephalitis in Cord Blood Transplant Recipients: a Prospective Multicenter Trial with a Historical Control Group.
    Biol Blood Marrow Transplant 2018 Feb 15. Epub 2018 Feb 15.
    Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan.
    Cord blood transplantation (CBT) is a distinct risk factor for human herpesvirus-6 (HHV-6) reactivation and HHV-6 encephalitis. In a prospective multicenter trial, we investigated the effects of prophylactic foscarnet (90 mg/kg intravenous infusion from day 7 to 27 after CBT) on the occurrence of HHV-6 reactivation, HHV-6 encephalitis, and acute graft-versus-host disease (aGVHD) in CBT recipients. Between 2014 and 2016, a total of 57 patients were included in a foscarnet-prophylaxis group. Read More

    A wild bootstrap approach for the Aalen-Johansen estimator.
    Biometrics 2018 Feb 16. Epub 2018 Feb 16.
    Institute of Statistics, Ulm University, Ulm, Germany.
    We suggest a wild bootstrap resampling technique for nonparametric inference on transition probabilities in a general time-inhomogeneous Markov multistate model. We first approximate the limiting distribution of the Nelson-Aalen estimator by repeatedly generating standard normal wild bootstrap variates, while the data is kept fixed. Next, a transformation using a functional delta method argument is applied. Read More

    Gut microbiota injury in allogeneic haematopoietic stem cell transplantation.
    Nat Rev Cancer 2018 Feb 16. Epub 2018 Feb 16.
    Department of Immunology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
    Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is considered to be the strongest curative immunotherapy for various malignancies (primarily, but not limited to, haematologic malignancies). However, application of allo-HSCT is limited owing to its life-threatening major complications, such as graft-versus-host disease (GVHD), relapse and infections. Recent advances in large-scale DNA sequencing technology have facilitated rapid identification of the microorganisms that make up the microbiota and evaluation of their interactions with host immunity in various diseases, including cancer. Read More

    HLA-Matched Sibling Vs. Unrelated Vs. Haploidentical Related Donor Allogeneic Hematopoietic Stem Cell Transplantation for Patients Aged Over 60 Years with Acute Myeloid Leukemia: a Single-Center Donor Comparison.
    Biol Blood Marrow Transplant 2018 Feb 12. Epub 2018 Feb 12.
    Department of Hematology, Institut Paoli-Calmettes, Marseille, France; Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm U1068, CNRS UMR 7258, Marseille, France; Aix-Marseille University, UM 105, Marseille, France.
    Haploidentical related donor (HRD) allogeneic hematopoietic stem cell transplantation (Allo-HSCT) was developed as a valid option for the treatment of acute myeloid leukemia (AML) in the absence of a matched donor. However, many investigators are reluctant to consider the use of this alternative in elderly patients, anticipating high morbidity. Here, we report a single-center comparison of HRD vs. Read More

    Extracorporeal photopheresis as second-line therapy for patients with acute graft-versus-host disease: does the number of cells treated matter?
    Transfusion 2018 Feb 15. Epub 2018 Feb 15.
    Division of Hematology, Medical University of Graz, Graz, Austria.
    Background: Extracorporeal photopheresis (ECP) has demonstrated efficacy as second-line treatment for steroid-refractory (SR) acute graft-versus-host disease (aGVHD). The aim of our study was to analyze whether the amount of ECP-treated cells in patients with SR, aGVHD has an impact on response at 1 month.

    Study Design And Methods: Data on white blood cells, lymphocytes, monocytes, mononuclear cells, and neutrophils, including absolute counts and counts per kilogram of body weight in ECP products from patients with aGVHD, were collected. Read More

    Effects of MicroRNA on Regulatory T Cells and Implications for Adoptive Cellular Therapy to Ameliorate Graft-versus-Host Disease.
    Front Immunol 2018 31;9:57. Epub 2018 Jan 31.
    Department of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota Cancer Center, Minneapolis, MN, United States.
    Regulatory T cells (Tregs) are key mediators of the immune system. MicroRNAs (miRNAs) are a family of ~22 nucleotide non-coding RNAs that are processed from longer precursors by the RNases Drosha and Dicer. miRNA regulates protein expression posttranscriptionally through mRNA destabilization or translational silencing. Read More

    Blockade of Host β2-Adrenergic Receptor Enhances Graft-versus-Tumor Effect through Modulating APCs.
    J Immunol 2018 Feb 14. Epub 2018 Feb 14.
    Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263;
    Allogeneic hematopoietic cell transplantation is a potential curative therapy for hematologic malignancies. Host APCs are pivotal to the desired graft-versus-tumor (GVT) effect. Recent studies have shown that β2-adrenergic receptor (β2AR) signaling can have an important impact on immune cell function, including dendritic cells (DCs). Read More

    Vascular access considerations for extracorporeal photopheresis.
    Transfusion 2018 Feb;58 Suppl 1:590-597
    Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Phoenix, Arizona.
    Extracorporeal photopheresis is an immunomodulatory therapy indicated for patients with cutaneous T-cell lymphoma, graft-versus-host disease, and heart or lung allograft rejection. Whole blood from the patient is drawn into the photopheresis instrument where it is separated into its components. Plasma, red blood cells, and the treated buffy coat are subsequently returned to the patient. Read More

    TGF-β-Induced CD8CD103Regulatory T Cells Show Potent Therapeutic Effect on Chronic Graft-versus-Host Disease Lupus by Suppressing B Cells.
    Front Immunol 2018 30;9:35. Epub 2018 Jan 30.
    Department of Clinical Immunology, The Third Affiliate Hospital of Sun Yat-sen University, Guangzhou, China.
    Lupus nephritis is one of most severe complications of systemic erythematosus lupus and current approaches are not curative for lupus nephritis. Although CD4Foxp3regulatory T cells (Treg) are crucial for prevention of autoimmunity, the therapeutic effect of these cells on lupus nephritis is not satisfactory. We previously reported that CD8CD103Treg inducedwith TGF-β1 and IL-2 (CD8CD103iTreg), regardless of Foxp3 expression, displayed potent immunosuppressive effect on Th cell response and had therapeutic effect on Th cell-mediated colitis. Read More

    Zinc supplementation plays a crucial role in T helper 9 differentiation in allogeneic immune reactions and non-activated T cells.
    J Trace Elem Med Biol 2018 Feb 6. Epub 2018 Feb 6.
    Institute of Immunology, RWTH Aachen University Hospital, Pauwelsstr. 30, 52074 Aachen, Germany. Electronic address:
    T helper (Th) 9 cells play a critical role in immune-mediated diseases, including allergic airway inflammation, autoimmune diseases, and cancer development. Thus, the promotion or suppression of Th9 cell differentiation, transcriptional control, and function is very important for a healthy immune system. Interestingly, T cell maturation, differentiation and function are highly dependent on the individuals' zinc status. Read More

    α-Antitrypsin Infusion for treatment of Steroid Resistant Acute Graft-versus-Host Disease.
    Blood 2018 Feb 2. Epub 2018 Feb 2.
    Blood and Marrow Transplantation Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, United States;
    Corticosteroid resistance following acute GVHD (SR-aGVHD) results in high morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT). Current immunosuppressive therapies for SR-aGVHD provide marginal effectiveness due to poor response or excessive toxicity, primarily from infection. Alpha-1 antitrypsin (AAT), a naturally abundant serine protease inhibitor, is capable of suppressing experimental GVHD by down-modulation of inflammation and increasing ratios of regulatory to effector T cells. Read More

    B-cell targeting in chronic Graft-versus-Host disease.
    Blood 2018 Feb 1. Epub 2018 Feb 1.
    Department of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, Minneapolis, MN, United States.
    Over the last decade our understanding of the pathophysiology of chronic graft-versus-host disease (cGVHD) has improved considerably. In this spotlight, we discuss emerging insights into the pathophysiology of cGVHD with a focus on B-cells. First, we summarize supporting evidence derived from mouse and human studies. Read More

    Allogeneic Matched Related Donor Bone Marrow Transplantation for Pediatric Patients With Severe Aplastic Anemia Using "Low-dose" Cyclophosphamide, ATG Plus Fludarabine.
    J Pediatr Hematol Oncol 2018 Feb 9. Epub 2018 Feb 9.
    Department of Pediatrics, Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center.
    Background: The combination of cyclophosphamide (CY) and antithymocyte globulin (ATG) has been used as a standard conditioning regimen for matched related donor transplantation in patients with severe aplastic anemia.

    Procedure: To decrease the regimen-related toxicity while maintaining appropriate engraftment and survival rates, fludarabine (FLU) was added to the regimen. Four pediatric patients received matched related donor bone marrow transplantation with CY (50 mg/kg×2) (instead of the 50 mg/kg×4 standard dosing), equine ATG (30 mg/kg×3), with the addition of FLU (30 mg/m×4). Read More

    Haploidentical HSCT for hemoglobinopathies: improved outcomes with TCRαβ/CD19-depleted grafts.
    Blood Adv 2018 Feb;2(3):263-270
    International Center for Transplantation in Thalassemia and Sickle Cell Anemia, Mediterranean Institute of Hematology, Policlinico Tor Vergata, Rome, Italy.
    We examined outcomes of haploidentical hematopoietic cell transplantation (haplo-HCT) using T-cell receptor αβ(TCRαβ)/CD19-depleted grafts (TCR group, 14 patients) in children with hemoglobinopathies. Patients received a preparative regimen consisting of busulfan, thiotepa, cyclophosphamide, and antithymocyte globulin preceded by fludarabine, hydroxyurea, and azathioprine. The median follow-up among surviving patients was 3. Read More

    A Controlled Trial of Sheng-Yu-Tang for Post-Hematopoietic Stem Cell Transplantation Leukemia Patients: A Proposed Protocol and Insights From a Preliminary Pilot Study.
    Integr Cancer Ther 2018 Feb 1:1534735418756736. Epub 2018 Feb 1.
    1 China Medical University, Taichung, Taiwan.
    Introduction: Hematopoietic stem cell transplantation has become a well-established treatment for hematologic disorders including acute leukemia. However, long-term survival rates following this procedure are still extremely low, due to posttransplantation relapse, infections, and graft-versus-host disease. We propose that adjunctive Chinese herbal medicine may benefit posttransplantation patients. Read More

    Pharmacokinetic and Pharmacodynamic Markers of Mycophenolic Acid Associated with Effective Prophylaxis for Acute Graft-Versus-Host Disease and Neutrophil Engraftment in Cord Blood Transplant Patients.
    Biol Blood Marrow Transplant 2018 Feb 7. Epub 2018 Feb 7.
    Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Sakyo-ku, Kyoto 606-8507, Japan.
    Mycophenolate mofetil (MMF) is a pro-drug of mycophenolic acid (MPA) and is frequently used to prevent acute graft-versus-host disease (aGVHD) in patients receiving hematopoietic stem cell transplants (HCT). However, optimal doses of MMF and target MPA concentrations in HCT patients have not been defined. In this study, relationships between pharmacokinetic or pharmacodynamic markers of MPA and successful aGVHD prevention and neutrophil engraftment were evaluated to inform individualized MPA treatments in HCT patients. Read More

    High Mutation Frequency of theGene in T Cells Results in Reconstitution of GPI Anchor/CD52T Cells That Can Give Early Immune Protection after Alemtuzumab-Based T Cell-Depleted Allogeneic Stem Cell Transplantation.
    J Immunol 2018 Feb 2. Epub 2018 Feb 2.
    Department of Hematology, Leiden University Medical Center, 2333ZA Leiden, the Netherlands; and.
    Alemtuzumab (ALM) is used for T cell depletion in the context of allogeneic hematopoietic stem cell transplantation (alloSCT) to prevent acute graft-versus-host disease and graft rejection. Following ALM-based T cell-depleted alloSCT, relatively rapid recovery of circulating T cells has been described, including T cells that lack membrane expression of the GPI-anchored ALM target Ag CD52. We show, in a cohort of 89 human recipients of an ALM-based T cell-depleted alloSCT graft, that early lymphocyte reconstitution always coincided with the presence of large populations of T cells lacking CD52 membrane expression. Read More

    Reprint of: Virus-Specific T Cells: Broadening Applicability.
    Biol Blood Marrow Transplant 2018 Mar;24(3S):S1-S6
    Center for Cancer and Immunology Research, Departments of Pediatrics and Microbiology, Immunology and Tropical Medicine, Children's National Medical Center and The George Washington University, Washington, District of Columbia. Electronic address:
    Virus infection remains an appreciable cause of morbidity and mortality after hematopoietic stem cell transplantation (HSCT). Although pharmacotherapy and/or antibody therapy may help prevent or treat viral disease, these drugs are expensive, toxic, and often ineffective due to primary or secondary resistance. Further, effective treatments are limited for many infections (eg, adenovirus, BK virus), which are increasingly detected after alternative donor transplants. Read More

    Second Malignancies after Hematopoietic Stem Cell Transplantation.
    Curr Treat Options Oncol 2018 Feb 8;19(2). Epub 2018 Feb 8.
    The Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel.
    Opinion Statement: Second malignancies are a rare but well-defined late complication after autologous and allogeneic hematopoietic stem-cell transplantation (SCT). Solid malignancies occur in up to 15% of patients 15 years after SCT with myeloablative conditioning, with no plateau in the incidence rates. They are responsible for 5-10% of late deaths after SCT. Read More

    Salvaged allogeneic hematopoietic stem cell transplantation for pediatric chemotherapy refractory acute leukemia.
    Oncotarget 2018 Jan 1;9(3):3143-3159. Epub 2017 Dec 1.
    Department of Hematology, China Aerospace Central Hospital, Beijing, China.
    There is an ongoing debate concerning the performance of salvaged allogeneic hematopoietic stem cell transplantation (allo-HSCT) in pediatric patients with acute refractory leukemia, in whom the prognosis is quite dismal. Few studies have ever been conducted on this subject. This may be partly due to missed opportunities by majority of the patients in such situations. Read More

    A Modified Post-Transplant Cyclophosphamide (PT-CY) Regimen, for Unmanipulated Haploidentical Marrow Transplantation, in Acute Myeloid Leukemia: a Multicenter Study.
    Biol Blood Marrow Transplant 2018 Feb 5. Epub 2018 Feb 5.
    Istituto di Ematologia, Policlinico Universitario A Gemelli, Universita' Cattolica, Roma, Italy. Electronic address:
    We are reporting a modified post-transplant cyclophosphamide (PT-CY) regimen, for unmanipulated haploidentical marrow transplants (HAPLO), in 150 patients with acute myeloid leukemia (AML). All patients received a myeloablative regimen, cyclosporine (CsA) on day 0, mycophenolate on day +1, and PT-CY 50 mg/kg, on days +3 and +5. The median age was 51 years (17-74), 51 patients (34%) had active disease at transplant, and the median follow up of surviving patients 903 days (150-1955). Read More

    Tacrolimus Optic Neuropathy.
    J Neuroophthalmol 2018 Feb 7. Epub 2018 Feb 7.
    Department of Ophthalmology (NR), Harkness Eye Institute, Columbia University, New York, New York; Deartment of Ophthalmology (KB), University of Montreal, Montreal, Quebec, Canada; Department of Ophthalmology (SL, DMC), Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts; and Department of Ophthalmology (SP), Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
    Background: Tacrolimus (FK506, Prograf) is a potent immunosuppressant, which inhibits cytokine synthesis and blocks T-cell development. Optic neuropathy from tacrolimus toxicity is very uncommon but, when present, can result in severe vision loss.

    Methods: Case series and review of the literature. Read More

    Organ damage mitigation with the Baskent Sickle Cell Medical Care Development Program (BASCARE).
    Medicine (Baltimore) 2018 Feb;97(6):e9844
    Department of Immunology, Faculty of Medicine, University of Baskent, Ankara, Turkey.
    The Eastern Mediterranean is among the regions where sickle cell disease (SCD) is common. The morbidity and mortality of this disease can be postponed to adulthood through therapies implemented in childhood. The present study focuses on the organ damage-reducing effects of the Baskent Sickle Cell Medical Care Development Program (BASCARE), which was developed by a team who lives in this region and has approximately 25 years of experience. Read More

    Protein dysregulation in graft versus host disease.
    Oncotarget 2018 Jan 15;9(1):1483-1491. Epub 2017 Dec 15.
    Department of Hematology, Ion Chiricuta Oncology Institute, Cluj Napoca, Romania.
    Allogeneic hematopoietic stem cell transplantation is a well-established treatment for many malignant and non-malignant hematological disorders. As a frequent complication in up to 50% of all patients, graft-versus-host disease is still the main cause for morbidity and non-relapse mortality. Diagnosis is usually done clinically, even though confirmation by pathology is often used to support the clinical findings. Read More

    Allogeneic hematopoietic stem cell transplantation for relapsed acute myeloid leukemia in ETO positive with reduced-intensity conditioning.
    Oncotarget 2018 Jan 3;9(1):524-538. Epub 2017 Nov 3.
    Center of Hematopoietic Stem Cell Transplantation, 307 Hospital of People's Liberation Army, Beijing, 100071, China.
    Objective: This research is conducted under the intention of exploring the efficacy and safety of reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the treatment of relapsed ETO positive acute myeloid leukemia (AML).

    Materials And Methods: Treatment of 15 cases referring to recurrent ETO positive acute myeloid leukemia in an army hospital from January 2010 to January 2013 through allo-HSCT with reduced-intensity conditioning. All participants belonged to the recurrent or refractory type, including 10 males and 5 females, aging from 16 to 48 years old, with the average age of 32. Read More

    Patients with Treatment-Requiring Chronic Graft versus Host Disease after Allogeneic Stem Cell Transplantation Have Altered Metabolic Profiles due to the Disease and Immunosuppressive Therapy: Potential Implication for Biomarkers.
    Front Immunol 2017 24;8:1979. Epub 2018 Jan 24.
    Section Hematology, Department of Medicine, Haukeland University Hospital, Bergen, Norway.
    Chronic graft versus host disease (cGVHD) is a common long-term complication after allogeneic hematopoietic stem cell transplantation. The objective of our study was to compare the metabolic profiles for allotransplant recipients and thereby identify metabolic characteristics of patients with treatment-requiring cGVHD. The study included 51 consecutive patients (29 men and 22 women; median age: 44 years, range: 15-66 years) transplanted with peripheral blood stem cells derived from human leukocyte antigen-matched family donors. Read More

    [Reduced-intensity umbilical cord blood transplantation for adult patients with fulminant aplastic anemia].
    Rinsho Ketsueki 2018 ;59(1):64-68
    Division of Oncology and Hematology, Jikei University.
    Allogeneic hematopoietic stem cell transplantation is recommended as a curative treatment option for fulminant aplastic anemia with no neutrophil despite the administration of granulocyte-colony stimulating factor. In the absence of an HLA-matched donor, unrelated cord blood transplantation (UCBT) is a treatment option that can be performed quickly. However, the optimal conditioning regimen of UCBT is yet to be established. Read More

    Efficacy of intracellular immune checkpoint-silenced DC vaccine.
    JCI Insight 2018 Feb 8;3(3). Epub 2018 Feb 8.
    Department of Hematopoietic Stem Cell Transplantation, Affiliated Hospital of Academy of Military Medical Sciences, Beijing, China.
    Background: DC-based tumor vaccines have had limited clinical success thus far. SOCS1, a key inhibitor of inflammatory cytokine signaling, is an immune checkpoint regulator that limits DC immunopotency.

    Methods: We generated a genetically modified DC (gmDC) vaccine to perform immunotherapy. Read More

    Allogeneic Hematopoietic Stem-Cell Transplantation for GATA2 Deficiency Using a Busulfan-Based Regimen.
    Biol Blood Marrow Transplant 2018 Feb 2. Epub 2018 Feb 2.
    Experimental Transplantation and Immunology Branch, National Cancer Institute, Bethesda, Maryland.
    Allogeneic hematopoietic stem cell transplantation (HSCT) reverses the bone marrow failure syndrome due to GATA2 deficiency. The intensity of conditioning required to achieve reliable engraftment and prevent relapse remains unclear. Here, we describe the results of a prospective study of HSCT in 22 patients with GATA2 deficiency using a busulfan-based conditioning regimen. Read More

    The Role of MicroRNAs in Myeloid Cells during Graft-versus-Host Disease.
    Front Immunol 2018 23;9. Epub 2018 Jan 23.
    Department of Hematology, Oncology and Stem Cell Transplantation, Freiburg University Medical Center, Freiburg, Germany.
    The successful treatment of various hematologic diseases with allogeneic hematopoietic cell transplantation is often limited by the occurrence of graft-versus-host disease (GvHD). Several microRNAs (miRs) have recently been shown to impact the biology of GvHD by regulating pro- as well as anti-inflammatory target genes. There is increasing evidence that a single miR can have different effects by preferentially targeting certain genes depending on the cell type that the miR is analyzed in. Read More


    Single Antigen-Mismatched Unrelated Hematopoietic Stem Cell Transplantation Using High-Dose Post-Transplantation Cyclophosphamide Is a Suitable Alternative for Patients Lacking HLA-Matched Donors.
    Biol Blood Marrow Transplant 2018 Feb 2. Epub 2018 Feb 2.
    Hematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Hematology and Oncology, Barcelona, Spain; Hemotherapy and Hemostasis Department, Barcelona, Spain; Institute Josep Carreras, Hospital Clínic, Barcelona, Spain. Electronic address:
    The optimal prophylaxis regimen for graft-versus-host disease (GVHD) in the setting of mismatched unrelated donor (MMUD) allogeneic hematopoietic stem cell transplantation (alloHSCT) is not defined. The use of high-dose post-transplant cyclophosphamide (PTCy) in haploidentical transplantation has proven feasible and effective in overcoming the negative impact of HLA disparity on survival. We hypothesized that PTCy could also be effective in the setting of MMUD transplantation. Read More

    "Diagnostic Utility of Endoscopy and Biopsy in Suspected Acute Gastrointestinal Graft Versus Host Disease (GI-GVHD) Following Haematopoietic Progenitor Cell Transplantation (HPCT)."
    Biol Blood Marrow Transplant 2018 Feb 1. Epub 2018 Feb 1.
    Royal Brisbane and Women's Hospital, Herston QLD AUSTRALIA; University of Queensland, St Lucia QLD AUSTRALIA.
    Background / Aim: Acute gastrointestinal graft versus host disease (GI-GVHD) following haematopoietic progenitor cell transplantation (HPCT) is a common and life-threatening complication. Endoscopic biopsy of the gastrointestinal tract is required for diagnosis. However, clear evidence to optimise this diagnostic approach is lacking, leading to variation in diagnostic sensitivity between institutions. Read More

    Tolerance Induction in HLA Disparate Living Donor Kidney Transplantation by Facilitating Cell-Enriched Donor Stem Cell Infusion: the importance of durable chimerism.
    Hum Immunol 2018 Feb 2. Epub 2018 Feb 2.
    Institute for Cellular Therapeutics, University of Louisville, Louisville, KY, USA.
    Successful solid organ transplantation currently requires the life-long use of medications to suppress the immune system in order to prevent transplant rejection. Drug-based immunosuppression significantly increases the risk of infection and cancer, as well as being very costly. Development of new therapies to minimize or eliminate entirely the need for anti-rejection drugs is of great interest to the transplant community. Read More

    Graft-versus-host Disease-free, Relapse-free Survival After HLA-identical Sibling Peripheral Blood Stem Cell Transplantation With Tacrolimus-based Graft-versus-host Disease Prophylaxis in Japanese Patients.
    Transplant Proc 2018 Jan - Feb;50(1):241-245
    Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
    The ideal post-allogeneic hematopoietic cell transplantation recovery is not just the cure of hematologic malignancies but also freedom from ongoing morbidity. Recent studies have revealed that HLA-identical sibling peripheral blood stem cell transplantation (PBSCT) had been providing impaired graft-versus-host disease (GVHD)-free relapse-free survival (GRFS) due to a higher risk of GVHD. Study on GVHD prophylaxis bears clinical reliance when focused on Japanese population because risk of GVHD differs among races. Read More

    Comparison of Rejection-Specific Genes in Peripheral Blood and Allograft Biopsy From Kidney Transplant.
    Transplant Proc 2018 Jan - Feb;50(1):115-123
    Department of Pharmacy, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China. Electronic address:
    Background: Although improved understanding and assessment of organ rejection significantly contribute to long-term allograft survival after kidney transplantation, reliable and predictive biomarkers that enable diagnoses of rejection state are lacking. Patient rejection of a kidney graft displays a specific blood and biopsy transcriptional pattern, raising the question of whether transcript biomarkers in blood could reflect events within the allograft.

    Methods: Differential expression genes were screened on large-scale transcriptomic data from blood and allograft biopsies, which included recipients undergoing rejection and recipients with stable renal function. Read More

    Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: A single-center experience.
    Leuk Res 2018 Jan 29;67:1-5. Epub 2018 Jan 29.
    Department of Blood & Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL, USA.
    Background: T- cell prolymphocytic leukemia (T- PLL) is a rare aggressive hematological malignancy. Alemtuzumab, an anti-CD52 humanized monoclonal antibody, is the treatment of choice for remission induction. Allogeneic hematopoietic cell transplantation (allo-HCT) has been described to induce durable remissions and improve survival, but data is limited. Read More

    Bayesian Networks: A New Approach to Predict Therapeutic Range Achievement of Initial Cyclosporine Blood Concentration After Pediatric Hematopoietic Stem Cell Transplantation.
    Drugs R D 2018 Feb 5. Epub 2018 Feb 5.
    EMR 3738, Ciblage, Thérapeutique en Oncologie, Faculté de Médecine et de Maïeutique Lyon-Sud Charles Mérieux, Université Claude Bernard Lyon 1, 165 chemin du Grand Revoyet-BP 12, 69921, Oullins Cedex, France.
    Background: Pediatric hematopoietic stem cell transplantation (HSCT) allows the treatment of numerous diseases, both malignant and non-malignant. Cyclosporine, a narrow therapeutic index drug, is the major immunosuppressant used to prevent graft-versus-host disease (GVHD), but may also cause severe adverse effects in case of overdosing.

    Objective: The objective of this study is to predict the initial cyclosporine residual blood concentration value after pediatric HSCT, and consequently the dose necessary to reach the therapeutic range, using a mathematical individual predictive model. Read More

    1 OF 590